N
Neurona Therapeutics
Cell therapy company focused on the development of breakthrough treatments for neurological disorders
About Neurona Therapeutics
Neurona Therapeutics is a pre-clinical stage biotechnology company founded by leading neuroscientists and stem cell pioneers from the University of California, San Francisco. The company focuses on the discovery and development of cell-based therapies aimed at treating intractable neurological diseases. Neurona Therapeutics operates in the biotechnology sector, specifically targeting neurological disorders that currently lack effective treatments. The business model revolves around creating therapeutic compositions of specific types of nerve cells, or neurons, for targeted delivery into the injured nervous system. This approach is built on a strong scientific foundation comprising decades of work in fundamental neuroscience, brain development, and stem cell biology. The company generates revenue through partnerships, grants, and potential future commercialization of its therapies. Neurona Therapeutics serves patients suffering from severe neurological conditions, offering them hope for improved quality of life through innovative medical solutions.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2008
- Headquarters
- South San Francisco, United States
- Employees
- 116
- Open positions
- 11
- Dealroom signal
- 55.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Medical & Healthcare, Neurology, Spinout, Biotech and Pharma, Cell Therapy, biotech medtech and e-health, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Apr 2026 | $650M | — | UCB | ↗ |
| LATE VCOther financing | Apr 2025 | $102M | $600M | Ysios Capital · The Column Group · Alexandria Venture Investments · LYFE Capital | ↗ |
Growth signals
Latest recorded traffic for Neurona Therapeutics is 5.1K monthly website visits, down 57.5% over the last three months. Neurona Therapeutics's team grew 27.5% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
South Carolina Research Authority
California Institute for Regenerative Medicine
Series A2 investors entered at this stage
The Column Group- AJAlexsis James
Series B and later17 investors entered at this stage
UCB Ventures
Alexandria Venture Investments- IVIronfire Ventures
Sphera Funds Management
Viking Global Investors
Cormorant Asset Management
Ysios Capital
LYFE Capital- SCSoleus Capital
Spur Capital Partners
UC Investments
Schroders Capital
YK Bioventures
Fidelity Investments- ECEuclidean Capital
Willett Advisors
Berkeley Frontier Fund
Other known investors2 additional known investors
UCB
University of California, San Francisco
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Neurona Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Neurona Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.